title: Prodromal states in schizophrenia.
abstract: The vulnerability-stress-coping (VSC) model is the most influential heuristic concept in understanding the course of schizophrenia, whose prodromal status still offers unsolved conceptual and methodological issues. Improved knowledge about the prodromal phase would provide a better understanding of the developing psychopathology and psychophysiology of schizophrenia and could also be of predictive value to attune therapeutic actions to the course of the illness more precisely. To shed more light on the characteristics of prodromal states, data from a German multicenter study on intermittent versus maintenance neuroleptic long-term treatment in schizophrenia (ANI study) were reanalyzed with respect to the prevalence and profile, nature, time course, and predictive value of prodromal symptoms in impending relapse. The results demonstrate that prodromes are a category of symptoms on their own, but they share variance with other symptom domains. Treatment side effects, psychotic symptoms, dysphoric mood, and social dysfunction are all associated with prodromal states--the direction of this association, however, is still to be clarified. Prodromal symptoms are also related to the neuroleptic treatment strategy and its relapse-preventive efficacy--findings that underscore neuroleptic maintenance medication in preventing both overt and subthreshold psychotic morbidity in schizophrenia.
authors.affiliation: Department of Psychiatry, Heinrich-Heine-University, Düsseldorf, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Gaebel
authors.forename: M
authors.initials: M
authors.lastname: Jänner
authors.forename: N
authors.initials: N
authors.lastname: Frommann
authors.forename: A
authors.initials: A
authors.lastname: Pietzcker
authors.forename: W
authors.initials: W
authors.lastname: Köpcke
authors.forename: M
authors.initials: M
authors.lastname: Linden
authors.forename: P
authors.initials: P
authors.lastname: Müller
authors.forename: F
authors.initials: F
authors.lastname: Müller-Spahn
authors.forename: J
authors.initials: J
authors.lastname: Tegeler
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D005260:Female; D005858:Germany; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data*; D011594:Psychometrics; D012008:Recurrence; D015203:Reproducibility of Results; D012559:Schizophrenia / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy; D012565:Schizophrenic Psychology; D012569:Schizotypal Personality Disorder / Q000145:classification / Q000175:diagnosis* / Q000523:psychology; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents